Shanqiu Liankang Files IPO Prospectus: Pioneering MPD Balance Method for Diabetes Reversal and Strategic Collaboration with JD Health in Internet-Plus Chronic Disease Management

On March 25, 2021, Shanqiu Liankang and JD Health at the Beijing headquarters of JD.comHolding the Strategic Cooperation Signing Ceremony，Both PartiesConvertCo-Construction“JD HealthDiabetes Nutrition Rehabilitation Center”, explore togetherServicesOn the JD Health platform10 million users with diabetes labels.

On that day, Professor Zou Dajin, a “National Renowned Doctor” in the inaugural cohort, former Chairman of the Diabetes Society of the Shanghai Medical Association, and Chief Medical Officer of Shanqiu Liankang, signed an agreement with JD Health as the academic leader of the “JD Health Diabetes Nutrition and Rehabilitation Center.” It is reported that Professor Zou joined Shanqiu Liankang in early 2020. This strategic partnership will enable Professor Zou and Shanqiu Liankang’s service support team to leverage the JD Health platform to provide more authoritative and professional online-to-offline chronic disease management services for patients with chronic conditions across China.

(Image provided by the company)

Ye Haifeng, CEO of Shanqiu Liankang, stated, “JD Health’s team conducted inspections and evaluations of dozens of leading chronic disease management institutions across China and ultimately selected Shanqiu Liankang as its strategic partner to jointly establish a Diabetes Nutrition and Rehabilitation Center. This demonstrates that Shanqiu Liankang’s services have stood the test of time. Shanqiu Liankang has already developed mature capabilities for standardized remote service delivery, enabling it to support endocrinologists nationwide using JD Cloud Clinic in providing standardized health management services, thereby ensuring systematic service processes, predictable service outcomes, and scalable service volume.”

China is a country with a large diabetic population. According to data released in the 9th edition of the IDF Diabetes Atlas by the International Diabetes Federation (IDF), the number of diabetes patients in China currently exceeds 116 million. As a chronic disease, diabetes is characterized not only by its long course and management challenges but also by numerous complications. Publicly available information shows thatIn 2019, China’s total expenditure on the treatment of diabetes and its complications reached RMB 758.2 billion, ranking second globally, with 80% of the costs attributed to the management of comorbidities.

Why Are Treatment Costs for Diabetes Complications Higher? First, the market lacks efficient whole-course management and services for diabetes. Patients face significant challenges in proactively controlling their blood glucose levels, resulting in low rates of target achievement. This leads to disease progression and an increased incidence of complications. The latest data published by the International Diabetes Federation (IDF) shows that in China, both the treatment and control rates for diabetes are suboptimal due to factors such as delayed diagnosis, insufficient attention, and non-adherence to blood glucose monitoring and medication regimens. Currently, fewer than 16% of Chinese patients achieve target blood glucose control.

Clinical data indicate that approximately 10 years after the onset of diabetes, 30%–40% of patients will develop at least one complication. Once these complications arise, they are difficult to reverse with pharmacological therapy alone. Therefore, clinical practice emphasizes the prevention of diabetes and its complications, improving the rate of adherence to management targets, and achieving scientific glycemic control.

Professor Zou Dajin stated, “The rate of achieving treatment targets for diabetes through medication alone is only around 30%. Improving this rate is difficult to accomplish solely within hospitals, which underscores the necessity of out-of-hospital management.”

Second, diabetic complications pose significant health risks, necessitating timely treatment for patients, while the cost of managing these complications is relatively high. According to World Health Organization statistics, there are more than 100 types of diabetic complications.DiabetesMore than 50% of deaths are attributable to diabetes complicated by cardiovascular and cerebrovascular diseases, and the rate of amputation among patients with diabetes is 10–20 times that of non-diabetic individuals.

Ye Haifeng stated, “China has a large population of patients with diabetes who are easily accessible; however, the market has long lacked providers of digital chronic disease management services that offer proven efficacy, remote delivery, and scalability.”

To address the aforementioned challenges in diabetes management,Shanqiu Liankang, as a multi-disciplinary out-of-hospital health management institution dedicated to serving individuals with metabolic disorders such as type 2 diabetes, obesity, and fatty liver disease, pioneered the “MPD Balance Method.” Leveraging big data and AI algorithms, it empowers patients with diabetes to achieve scientific glycemic control and restore their health.

Yan Yanchun, Chairman of Shanqiu Liankang, stated, “Professor Eric Seeman, Global Partner of Shanqiu Liankang and Director of the Lifestyle Medicine Center at Duke University in the United States, has served more than 8,000 patients with metabolic diseases in the U.S. In China, Professor Seeman, together with Professor Zou Dajin and multiple other experts, has achieved successful reversal of diabetes in over 1,000 Chinese patients,”Achieved a 99% medication reduction rate, a 44% medication discontinuation rate, and an average decrease in glycated hemoglobin of 1.46%.”

Leveraging the proven efficacy of the MPD Balance Method, Shanghai Shanqiu Liankang Health Management Co., Ltd. has the confidence to adopt a “performance-based fee” model—a feat that remains elusive for most chronic disease management enterprises. According to reports, Shanqiu Liankang enters into performance-based agreements with clients opting for its diabetes reversal services. The company assesses each patient’s individual condition to formulate personalized reversal goals and treatment plans, guaranteeing that these targets will be met within the management period. If the agreed-upon outcomes are not achieved, a refund is provided.

After more than a year of refinement, Shanqiu Liankang has established the capability to deliver digital chronic disease management services that are proven in efficacy, remotely accessible, and scalable. “This strategic partnership with JD Health is just the beginning; Shanqiu Liankang will also collaborate with multiple leading Chinese insurance companies to advance the integration of diabetes management and insurance products.”

Yan Yanchun stated, “We are not only focusing on digital out-of-hospital health management services for individuals with metabolic diseases, but also continuously expanding our offline service footprint. Last year, we established eight health management bases or centers across China, and we plan to cover most major cities in the country in the future. These service locations will provide on-the-ground support for online customers of the JD Health platform, delivering a seamless online-to-offline (O2O) service experience.”

JD Health has partnered with Professor Zou Dajin, a leading expert in endocrinology, and Shanqiu Liankang, a professional out-of-hospital health management institution, to further serve diabetic patients on the JD Health platform by providing more authoritative and specialized online-to-offline chronic disease management services.

On one side stands JD Health, a leading enterprise in internet healthcare. It has established a comprehensive “Internet + Healthcare” ecosystem, with products and services spanning the entire industrial chain of pharmaceutical and health physical goods, the full spectrum of medical processes, all health-related scenarios, and the entire user lifecycle. Targeting patients with metabolic diseases, particularly diabetes, JD Health leverages artificial intelligence, big data, IoT technologies, along with its advantages in medical resources and supply chain capabilities, to provide integrated online-to-offline management services that address the chronic disease management needs of patients.

On one side stands Professor Zou Dajin, an endocrinology expert who employs a professional and scientifically grounded MPD Balance Method. This approach helps patients with diabetes achieve rational blood glucose control and even reverse the disease, thereby restoring their health. As a specialist in endocrinology, Professor Zou has earned patient trust and an excellent reputation through his professional expertise.

On one side stands Shanqiu Liankang, a professional out-of-hospital health management enterprise. Its pioneering MPD Balance Method has demonstrated excellent clinical outcomes. After more than a year of refinement, the company has established mature, standardized capabilities for both remote service delivery and offline services, ensuring systematic service processes, predictable service outcomes, and scalable service volume.

Today, the three parties are collaborating to leverage their respective strengths in building a professional and authoritative online-to-offline (O2O) chronic disease management service. Specifically, the JD Health platform has access to a large population of diabetic patients with suboptimal self-management outcomes; Shanghai Shanqiu Liankang Health Management Co., Ltd. provides specialized, standardized chronic disease management solutions that are replicable and scalable; and endocrinology expert Zou Dajin leverages his influence and professional expertise to attract more endocrinologists to join the initiative, thereby serving a greater number of diabetic patients.

Shanqiu Liankang revealed: “In the future, JD Health, Professor Zou Dajin, and Shanqiu Liankang will leverage their respective strengths to jointly explore specialized centers for chronic disease management, build a comprehensive online ecosystem for chronic disease management, and collectively promote the deep penetration and healthy development of the ‘Internet + Chronic Disease Management’ model.”